Welcome to our dedicated page for Helix Acqsn II SEC filings (Ticker: HLXB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with Helix Acquisition Corp. II (HLXB) document its formation and evolution from a healthcare-focused SPAC to the public company now known as BridgeBio Oncology Therapeutics, Inc. Investors can review the registration statements, current reports, and proxy materials that describe each step in this process.
Key filings include the IPO registration statement and related documents that detail the issuance of Class A ordinary shares, the trust account structure, and the rights of public shareholders. Current reports on Form 8-K provide official records of material events, such as the announcement and terms of the business combination with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), the effectiveness of the Form S-4 registration statement, and the results of the extraordinary general meeting at which shareholders approved the transaction and related proposals.
A Form 8-K filed after the August 11, 2025 closing describes the domestication of Helix from the Cayman Islands to Delaware, the merger of a Helix subsidiary with BBOT, the conversion of BBOT equity into shares and options of the public company, and the change of Helix’s name to BridgeBio Oncology Therapeutics, Inc. That filing also notes that the common stock of the renamed company is listed on the Nasdaq Global Market under the symbol BBOT, marking the transition from the HLXB SPAC ticker to the operating biopharmaceutical company.
Additional registration materials, such as the Form S-1 filed by BridgeBio Oncology Therapeutics, Inc. to register shares for resale by selling securityholders, further outline the post-combination capital structure and registration rights. On this page, Stock Titan surfaces these SEC documents and applies AI-powered summaries to help readers understand the purpose and main points of each filing, including business combination terms, share issuances, and changes in corporate structure linked to HLXB’s history.
Helix Acquisition Corp. II (Nasdaq: HLXB) has reached a key milestone in its proposed merger with TheRas, Inc. (doing business as BridgeBio Oncology Therapeutics, “BBOT”). The company disclosed in an 8-K filing dated 11 July 2025 that the U.S. Securities and Exchange Commission declared the joint Registration Statement on Form S-4 effective on 10 July 2025. The effective S-4 contains the combined proxy statement/prospectus that will be mailed to Helix shareholders of record as of 30 June 2025 for a vote on the business combination.
Under the Business Combination Agreement (signed 28 Feb 2025 and amended 17 Jun 2025), Helix will merge with BBOT through a wholly owned subsidiary, after which the resulting public entity will be renamed BridgeBio Oncology Therapeutics (“PubCo”). The filing notes that completion of the transaction remains subject to customary conditions, including shareholder approval and possible regulatory clearances. Exhibit 99.1 (press release) was furnished—not filed—under Item 7.01.
The filing reiterates extensive forward-looking statement and risk disclosures typical of SPAC transactions, highlighting uncertainties such as shareholder redemptions, regulatory review, clinical-development outcomes for BBOT’s candidates (ONKORAS-101, BREAKER-101, BBO-11818, BBO-8520, BBO-10203) and general market conditions.
- Next step: distribution of the definitive proxy statement/prospectus to shareholders and scheduling of the shareholder meeting.
- Ticker and listing: Helix’s Class A ordinary shares continue to trade on Nasdaq under “HLXB” until closing.
Helix Acquisition Corp. II (symbol: HLXB) has filed a Form S-4 detailing its proposed business combination with TheRas, Inc. (doing business as BridgeBio Oncology Therapeutics, “BBOT”). The filing registers up to 28 million shares of common stock to be issued in connection with the transaction and outlines a multi-step process that will (i) domesticate Helix from the Cayman Islands to Delaware, (ii) merge a Helix subsidiary with and into BBOT, and (iii) rename the surviving public entity “BridgeBio Oncology Therapeutics, Inc.”
Structure & Timeline: • On February 27-28, 2025 Helix’s board unanimously approved the Business Combination Agreement, later amended on June 17, 2025. • Domestication is expected one business day prior to closing; immediately thereafter, Helix Class A ordinary shares (other than redeemed Public Shares) will convert one-for-one into PubCo common stock. • Sponsor mechanics include the surrender of an undetermined number of “Sponsor Forfeited Shares” and a conversion of remaining Class B shares into Class A prior to domestication, potentially reducing founder dilution. • At merger effectiveness, each outstanding BBOT share will convert into PubCo shares at a “Consideration Ratio” derived from an Equity Value of US $461,051,546 divided by the redemption price for Helix Public Shares. Outstanding BBOT options will convert into equivalent PubCo options using the same ratio.
Registered Securities & Consideration: • Aggregate merger consideration equals the Equity Value divided by the as-yet-undetermined redemption price. • The S-4 covers issuance of up to 28,000,000 PubCo shares, inclusive of merger consideration and option exercises. • No cash consideration is described; the transaction is entirely share-for-share.
Regulatory & Status Flags: • Helix is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. • The registration statement is preliminary; securities cannot be issued until the SEC declares effectiveness. • A customary ability to postpone effectiveness until further amendment is reserved.
Key Implications for Investors:
- The filing marks a critical step toward closing a de-SPAC transaction that would transition Helix into an oncology-focused operating company.
- Equity valuation of approximately $461 million provides an initial reference point for PubCo, although the final share count will depend on Public Share redemptions.
- Founder-share forfeiture and conversion mechanics could mitigate dilution to public shareholders.
- Registration of 28 million shares signals potentially significant dilution relative to Helix’s current public float.